ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Acquired by Pacer Advisors Inc.

by · The Markets Daily

Pacer Advisors Inc. lifted its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 23,259.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 568,343 shares of the specialty pharmaceutical company’s stock after acquiring an additional 565,910 shares during the period. Pacer Advisors Inc. owned 2.70% of ANI Pharmaceuticals worth $33,907,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the stock. Texas Permanent School Fund Corp boosted its stake in shares of ANI Pharmaceuticals by 1.3% during the second quarter. Texas Permanent School Fund Corp now owns 13,372 shares of the specialty pharmaceutical company’s stock valued at $852,000 after acquiring an additional 178 shares during the last quarter. Louisiana State Employees Retirement System boosted its stake in ANI Pharmaceuticals by 2.7% in the 2nd quarter. Louisiana State Employees Retirement System now owns 7,700 shares of the specialty pharmaceutical company’s stock worth $490,000 after buying an additional 200 shares during the last quarter. Arizona State Retirement System boosted its stake in ANI Pharmaceuticals by 4.7% in the 2nd quarter. Arizona State Retirement System now owns 4,702 shares of the specialty pharmaceutical company’s stock worth $299,000 after buying an additional 211 shares during the last quarter. Simplicity Wealth LLC boosted its stake in ANI Pharmaceuticals by 3.5% in the 2nd quarter. Simplicity Wealth LLC now owns 6,733 shares of the specialty pharmaceutical company’s stock worth $429,000 after buying an additional 227 shares during the last quarter. Finally, California State Teachers Retirement System boosted its stake in ANI Pharmaceuticals by 1.5% in the 1st quarter. California State Teachers Retirement System now owns 16,175 shares of the specialty pharmaceutical company’s stock worth $1,118,000 after buying an additional 233 shares during the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. StockNews.com lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. HC Wainwright restated a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, November 11th. Truist Financial raised their price objective on ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a report on Tuesday, October 22nd. Raymond James raised their price objective on ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a report on Wednesday, September 18th. Finally, Piper Sandler initiated coverage on ANI Pharmaceuticals in a report on Friday, October 11th. They issued an “overweight” rating and a $68.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, ANI Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $77.33.

Get Our Latest Analysis on ANI Pharmaceuticals

ANI Pharmaceuticals Trading Up 1.9 %

NASDAQ ANIP opened at $56.91 on Friday. The company’s fifty day moving average price is $58.34 and its two-hundred day moving average price is $61.03. ANI Pharmaceuticals, Inc. has a 12 month low of $48.20 and a 12 month high of $70.81. The company has a market capitalization of $1.20 billion, a price-to-earnings ratio of -103.47 and a beta of 0.71. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97.

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last announced its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.09 by $0.25. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The firm had revenue of $148.30 million for the quarter, compared to analysts’ expectations of $144.37 million. During the same quarter in the prior year, the firm posted $1.05 earnings per share. ANI Pharmaceuticals’s revenue for the quarter was up 12.5% compared to the same quarter last year. As a group, research analysts predict that ANI Pharmaceuticals, Inc. will post 3.87 earnings per share for the current fiscal year.

ANI Pharmaceuticals Profile

(Free Report)

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.

Further Reading

Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report).